Phosphodiesterase 10 inhibitors: New disease modifying drugs for Parkinson's disease?

Current Medicinal Chemistry

Volumn 21, Issue 10, 2014, Pages 1171-1187

  Garcia A M ^a   Redondo, M ^a   Martinez, A ^a   Gil, C ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

CAMP; Drug design; Neurodegenerative diseases; Parkinson's disease; PDE10A inhibitors

Indexed keywords

6,7 DIMETHOXYQUINAZOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; HETEROCYCLIC COMPOUND; HYDRAZONE DERIVATIVE; LEVODOPA; PAPAVERINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE INHIBITOR; PQ 10; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR DISTRIBUTION; CRYSTAL STRUCTURE; DRUG MECHANISM; ENZYME SUBSTRATE COMPLEX; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; NONHUMAN; PARKINSON DISEASE; PROTEIN DATA BANK; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION;

ANTIPARKINSON AGENTS; CORPUS STRIATUM; CYCLIC AMP; DRUG DESIGN; GENE EXPRESSION; HUMANS; MODELS, MOLECULAR; MOTOR ACTIVITY; PARKINSON DISEASE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84896288822     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666131228221749     Document Type: Article

References (95)

1. Essayan, D. M. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem. Pharmacol., 1999, 57, 965-973. (Pubitemid 29168544)
2. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther., 2006, 109, 366-398. (Pubitemid 43132818)
3. Bollen, E.; Prickaerts, J. Phosphodiesterases in neurodegenerative disorders. IUBMB Life, 2012, 64, 965-970.
4. Conti, M.; Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem., 2007, 76, 481-511.
5. Bingham, J.; Sudarsanam, S.; Srinivasan, S. Profiling human phosphodiesterase genes and splice isoforms. Biochem. Biophys. Res. Commun., 2006, 350, 25-32. (Pubitemid 44466570)
6. Keravis, T.; Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br. J. Pharmacol., 2012, 165, 1288-1305.
7. Lakics, V.; Karran, E. H.; Boess, F. G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology, 2010, 59, 367-374.
8. Schmidt, C. J. Phosphodiesterase inhibitors as potential cognition enhancing agents. Curr. Top Med. Chem., 2010, 10, 222-230.
9. Menniti, F. S.; Faraci, W. S.; Schmidt, C. J. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov., 2006, 5, 660-670. (Pubitemid 44151604)
10. Johansson, E. M.; Reyes-Irisarri, E.; Mengod, G. Comparison of cAMP-specific phosphodiesterase mRNAs distribution in mouse and rat brain. Neurosci. Lett., 2012, 525, 1-6.
11. Malmersjo, S.; Liste, I.; Dyachok, O.; Tengholm, A.; Arenas, E.; Uhlen, P. Ca2+ and cAMP signaling in human embryonic stem cell-derived dopamine neurons. Stem Cells Dev., 2010, 19, 1355-1364.
12. Francis, S. H.; Blount, M. A.; Corbin, J. D. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol. Rev., 2011, 91, 651-690.
13. Seeger, T. F.; Bartlett, B.; Coskran, T. M.; Culp, J. S.; James, L. C.; Krull, D. L.; Lanfear, J.; Ryan, A. M.; Schmidt, C. J.; Strick, C. A.; Varghese, A. H.; Williams, R. D.; Wylie, P. G.; Menniti, F. S. Immunohistochemical localization of PDE10A in the rat brain. Brain Res., 2003, 985, 113-126. (Pubitemid 37088176)
14. Threlfell, S.; Sammut, S.; Menniti, F. S.; Schmidt, C. J.; West, A. R. Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J. Pharmacol. Exp. Ther., 2009, 328, 785-795.
15. Coskran, T. M.; Morton, D.; Menniti, F. S.; Adamowicz, W. O.; Kleiman, R. J.; Ryan, A. M.; Strick, C. A.; Schmidt, C. J.; Stephenson, D. T. Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J. Histochem. Cytochem., 2006, 54, 1205-1213. (Pubitemid 44623341)
16. Schmidt, C. J.; Chapin, D. S.; Cianfrogna, J.; Corman, M. L.; Hajos, M.; Harms, J. F.; Hoffman, W. E.; Lebel, L. A.; McCarthy, S. A.; Nelson, F. R.; Proulx-La France, C.; Majchrzak, M. J.; Ramirez, A. D.; Schmidt, K.; Seymour, P. A.; Siuciak, J. A.; Tingley, F. D., 3rd; Williams, R. D.; Verhoest, P. R.; Menniti, F. S. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J. Pharmacol. Exp. Ther., 2008, 325, 681-690. (Pubitemid 351574819)
17. Kehler, J.; Nielsen, J. PDE10A inhibitors: novel therapeutic drugs for schizophrenia. Curr. Pharm. Des., 2011, 17, 137-150.
18. Giampa, C.; Patassini, S.; Borreca, A.; Laurenti, D.; Marullo, F.; Bernardi, G.; Menniti, F. S.; Fusco, F. R. Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. Neurobiol. Dis., 2009, 34, 450-456.
19. Chappie, T.; Humphrey, J.; Menniti, F.; Schmidt, C. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape. Curr. Opin. Drug Discov. Devel., 2009, 12, 458-467.
20. Giampa, C.; Laurenti, D.; Anzilotti, S.; Bernardi, G.; Menniti, F. S.; Fusco, F. R. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PLoS One, 2010, 5, e13417.
21. Ke, H.; Wang, H. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr. Top. Med. Chem., 2007, 7, 391-403. (Pubitemid 46358652)
22. Zhang, K. Y.; Card, G. L.; Suzuki, Y.; Artis, D. R.; Fong, D.; Gillette, S.; Hsieh, D.; Neiman, J.; West, B. L.; Zhang, C.; Milburn, M. V.; Kim, S. H.; Schlessinger, J.; Bollag, G. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol. Cell, 2004, 15, 279-286. (Pubitemid 38950974)
23. Wang, H.; Liu, Y.; Hou, J.; Zheng, M.; Robinson, H.; Ke, H. Structural insight into substrate specificity of phosphodiesterase 10. Proc. Natl. Acad. Sci. U S A, 2007, 104, 5782-5787. (Pubitemid 47175611)
24. Ke, H.; Wang, H.; Ye, M. Structural insight into the substrate specificity of phosphodiesterases. Handb. Exp. Pharmacol., 2011, 121-134.
25. Wang, H.; Robinson, H.; Ke, H. The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10. J. Mol. Biol., 2007, 371, 302-307. (Pubitemid 47048279)
26. Fujishige, K.; Kotera, J.; Michibata, H.; Yuasa, K.; Takebayashi, S.; Okumura, K.; Omori, K. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem., 1999, 274, 18438-18445.
27. Loughney, K.; Snyder, P. B.; Uher, L.; Rosman, G. J.; Ferguson, K.; Florio, V. A. Isolation and characterization of PDE10A, a novel human 3', 5'-cyclic nucleotide phosphodiesterase. Gene, 1999, 234, 109-117. (Pubitemid 29294097)
28. Soderling, S. H.; Bayuga, S. J.; Beavo, J. A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. U S A, 1999, 96, 7071-7076. (Pubitemid 29275011)
29. Gross-Langenhoff, M.; Hofbauer, K.; Weber, J.; Schultz, A.; Schultz, J. E. cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J. Biol. Chem., 2006, 281, 2841-2846. (Pubitemid 43845749)
30. Ho, G. D.; Michael Seganish, W.; Bercovici, A.; Tulshian, D.; Greenlee, W. J.; Van Rijn, R.; Hruza, A.; Xiao, L.; Rindgen, D.; Mullins, D.; Guzzi, M.; Zhang, X.; Bleickardt, C.; Hodgson, R. The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg. Med. Chem. Lett., 2012, 22, 2585-2589.
31. Andersen, O. A.; Schonfeld, D. L.; Toogood-Johnson, I.; Felicetti, B.; Albrecht, C.; Fryatt, T.; Whittaker, M.; Hallett, D.; Barker, J. Cross-linking of protein crystals as an aid in the generation of binary protein-ligand crystal complexes, exemplified by the human PDE10a-papaverine structure. Acta Crystallogr. D Biol. Crystallogr., 2009, 65, 872-874.
32. Kehler, J.; Ritzen, A.; Langgard, M.; Petersen, S. L.; Farah, M. M.; Bundgaard, C.; Christoffersen, C. T.; Nielsen, J.; Kilburn, J. P. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors. Bioorg. Med. Chem. Lett., 2011, 21, 3738-3742.
33. Handa, N.; Mizohata, E.; Kishishita, S.; Toyama, M.; Morita, S.; Uchikubo-Kamo, T.; Akasaka, R.; Omori, K.; Kotera, J.; Terada, T.; Shirouzu, M.; Yokoyama, S. Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP. J. Biol. Chem., 2008, 283, 19657-19664.
34. Bauer, U.; Giordanetto, F.; Bauer, M.; O'Mahony, G.; Johansson, K. E.; Knecht, W.; Hartleib-Geschwindner, J.; Carlsson, E. T.; Enroth, C. Discovery of 4-hydroxy-1, 6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors. Bioorg. Med. Chem. Lett., 2012, 22, 1944-1948.
35. Hu, E.; Kunz, R. K.; Rumfelt, S.; Chen, N.; Burli, R.; Li, C.; Andrews, K. L.; Zhang, J.; Chmait, S.; Kogan, J.; Lindstrom, M.; Hitchcock, S. A.; Treanor, J. Discovery of potent, selective, and metabolically stable 4-(pyridin-3-yl) cinnolines as novel phosphodiesterase 10A (PDE10A) inhibitors. Bioorg. Med. Chem. Lett., 2012, 22, 2262-2265.
36. Malamas, M. S.; Ni, Y.; Erdei, J.; Stange, H.; Schindler, R.; Lankau, H. J.; Grunwald, C.; Fan, K. Y.; Parris, K.; Langen, B.; Egerland, U.; Hage, T.; Marquis, K. L.; Grauer, S.; Brennan, J.; Navarra, R.; Graf, R.; Harrison, B. L.; Robichaud, A.; Kronbach, T.; Pangalos, M. N.; Hoefgen, N.; Brandon, N. J. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors. J. Med. Chem., 2011, 54, 7621-7638.
37. Malamas, M. S.; Stange, H.; Schindler, R.; Lankau, H. J.; Grunwald, C.; Langen, B.; Egerland, U.; Hage, T.; Ni, Y.; Erdei, J.; Fan, K. Y.; Parris, K.; Marquis, K. L.; Grauer, S.; Brennan, J.; Navarra, R.; Graf, R.; Harrison, B. L.; Robichaud, A.; Kronbach, T.; Pangalos, M. N.; Brandon, N. J.; Hoefgen, N. Novel triazines as potent and selective phosphodiesterase 10A inhibitors. Bioorg. Med. Chem. Lett., 2012, 22, 5876-5884.
38. Rzasa, R. M.; Hu, E.; Rumfelt, S.; Chen, N.; Andrews, K. L.; Chmait, S.; Falsey, J. R.; Zhong, W.; Jones, A. D.; Porter, A.; Louie, S. W.; Zhao, X.; Treanor, J. J.; Allen, J. R. Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux. Bioorg. Med. Chem. Lett., 2012, 22, 7371-7375.
39. Hu, E.; Kunz, R. K.; Chen, N.; Rumfelt, S.; Siegmund, A.; Andrews, K.; Chmait, S.; Zhao, S.; Davis, C.; Chen, H.; Lester-Zeiner, D.; Ma, J.; Biorn, C.; Shi, J.; Porter, A.; Treanor, J.; Allen, J. R. Design, optimization, and biological evaluation of novel keto-benzimidazoles as potent and selective inhibitors of phosphodiesterase 10A (PDE10A). J. Med. Chem., 2013, doi:10.1021/jm401234w.
40. Höfgen, N.; Stange, H.; Schindler, R.; Lankau, H. J.; Grunwald, C.; Langen, B.; Egerland, U.; Tremmel, P.; Pangalos, M. N.; Marquis, K. L.; Hage, T.; Harrison, B. L.; Malamas, M. S.; Brandon, N. J.; Kronbach, T. Discovery of imidazo[1, 5-a]pyrido[3, 2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors. J. Med. Chem., 2010, 53, 4399-4411.
41. Helal, C. J.; Kang, Z.; Hou, X.; Pandit, J.; Chappie, T. A.; Humphrey, J. M.; Marr, E. S.; Fennell, K. F.; Chenard, L. K.; Fox, C.; Schmidt, C. J.; Williams, R. D.; Chapin, D. S.; Siuciak, J.; Lebel, L.; Menniti, F.; Cianfrogna, J.; Fonseca, K. R.; Nelson, F. R.; O'Connor, R.; MacDougall, M.; McDowell, L.; Liras, S. Use of structurebased design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia. J. Med. Chem., 2011, 54, 4536-4547.
42. Verhoest, P. R.; Chapin, D. S.; Corman, M.; Fonseca, K.; Harms, J. F.; Hou, X.; Marr, E. S.; Menniti, F. S.; Nelson, F.; O'Connor, R.; Pandit, J.; Proulx-Lafrance, C.; Schmidt, A. W.; Schmidt, C. J.; Suiciak, J. A.; Liras, S. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3- yl)-phenoxy methyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J. Med. Chem., 2009, 52, 5188-5196.
43. Lu, H.; Goren, A. C.; Zhan, C. G. Characterization of the structures of phosphodiesterase 10 binding with adenosine 3', 5'-monophosphate and guanosine 3', 5'-monophosphate by hybrid quantum mechanical/molecular mechanical calculations. J. Phys. Chem. B., 2010, 114, 7022-7028.
44. Heikaus, C. C.; Pandit, J.; Klevit, R. E. Cyclic nucleotide binding GAF domains from phosphodiesterases: structural and mechanistic insights. Structure, 2009, 17, 1551-1557.
45. Hofbauer, K.; Schultz, A.; Schultz, J. E. Functional chimeras of the phosphodiesterase 5 and 10 tandem GAF domains. J. Biol. Chem., 2008, 283, 25164-25170.
46. Fujishige, K.; Kotera, J.; Omori, K. Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A. Eur. J. Biochem., 1999, 266, 1118-1127. (Pubitemid 30010131)
47. Xie, Z.; Adamowicz, W. O.; Eldred, W. D.; Jakowski, A. B.; Kleiman, R. J.; Morton, D. G.; Stephenson, D. T.; Strick, C. A.; Williams, R. D.; Menniti, F. S. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience, 2006, 139, 597-607.
48. Nagatsua, T.; Sawadab, M. L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat. Disord., 2009, 15 Suppl 1, S3-S8.
49. Giorgi, M.; Melchiorri, G.; Nuccetelli, V.; D'Angelo, V.; Martorana, A.; Sorge, R.; Castelli, V.; Bernardi, G.; Sancesario, G. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology. Neurobiol. Dis., 2011, 43, 293-303.
50. Girault, J. A. Integrating neurotransmission in striatal medium spiny neurons. Adv. Exp. Med. Biol., 2012, 970, 407-429.
51. Nishi, A.; Snyder, G. L. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. J. Pharmacol. Sci., 2010, 114, 6-16.
52. Doorn, K. J.; Lucassen, P. J.; Boddeke, H. W.; Prins, M.; Berendse, H. W.; Drukarch, B.; van Dam, A. M. Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease. Prog. Neurobiol., 2012, 98, 222-238.
53. Sanderson, T. M.; Sher, E. The role of phosphodiesterases in hippocampal synaptic plasticity. Neuropharmacology, 2013, 74, 86-95.
54. Hebb, A. L.; Robertson, H. A. PDEs as drug targets for CNS immune disorders. Curr. Opin. Investig. Drugs, 2008, 9, 744-753. (Pubitemid 351950871)
55. Dworkin, S.; Mantamadiotis, T. Targeting CREB signalling in neurogenesis. Expert Opin. Ther. Targets, 2010, 14, 869-879.
56. Xu, Y.; Zhang, H. T.; O'Donnell, J. M. Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders. Handb. Exp. Pharmacol., 2011, 204, 447-485.
57. Blokland, A.; Menniti, F. S.; Prickaerts, J. PDE inhibition and cognition enhancement. Expert. Opin. Ther. Pat., 2012, 22, 349-354.
58. Siuciak, J. A.; McCarthy, S. A.; Chapin, D. S.; Fujiwara, R. A.; James, L. C.; Williams, R. D.; Stock, J. L.; McNeish, J. D.; Strick, C. A.; Menniti, F. S.; Schmidt, C. J. Genetic deletion of the striatumenriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology, 2006, 51, 374-385. (Pubitemid 44061880)
59. Siuciak, J. A.; Chapin, D. S.; Harms, J. F.; Lebel, L. A.; McCarthy, S. A.; Chambers, L.; Shrikhande, A.; Wong, S.; Menniti, F. S.; Schmidt, C. J. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology, 2006, 51, 386-396. (Pubitemid 44061894)
60. Kotera, J.; Sasaki, T.; Kitazawa, T.; Ishii, T.; Morimoto, H.; Yamada, H. Treatment of Parkinson's disease and enhacement of dopamine signal using PDE10 inhibitor. US 8338420, 2009.
61. Siuciak, J.; Chapin, D. S.; McCarthy, S. A.; Harms, J.; Schmidt, C. J.; Shrikhande, A.; Wong, S.; Williams, R.; Menniti, F.; James, L.; Strick, C.; Stock, J.; McNeish, J. PDE10 knockoutmice: behavioral characterization and effects of papaverine, a PDE10 inhibitor. Schizophenia Res., 2003, 60, 116.
62. Giralt, A.; Saavedra, A.; Carreton, O.; Arumi, H.; Tyebji, S.; Alberch, J.; Perez-Navarro, E. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a huntington's disease mouse model. Hippocampus, 2013, doi:10.1002/hipo.22128.
63. Guibinga, G. H.; Murray, F.; Barron, N. HPRT-deficiency dysregulates cAMP-PKA signaling and phosphodiesterase 10A expression: Mechanistic insight and potential target for Lesch-Nyhan disease? PLoS One, 2013, 8, e63333.
64. Fredholm, B. B.; Fuxe, K.; Agnati, L. Effect of some phosphodiesterase inhibitors on central dopamine mechanisms. Eur. J. Pharmacol., 1976, 38, 31-38.
65. Geschwindner, S.; Dekker, N.; Horsefield, R.; Tigerstrom, A.; Johansson, P.; Scott, C. W.; Albert, J. S. Development of a platebased optical biosensor fragment screening methodology to identify phosphodiesterase 10A inhibitors. J. Med. Chem., 2013, 56, 3228-3234.
66. Allen, M. P.; Chappie, T. A.; Humphrey, J. M.; Liras, S. Tetrahydroisoquinoline derivatives of quinazoline and isoquinoline. US20050182079, 2005.
67. Pandit, J. Crystal structure of catalytic domain of rat 3', 5'-cyclic nucleotide phosphodiesterase (PDE10) inhibitor complex and uses in the discovery of psychotherapeutic drugs. US20050202550, 2005.
68. Chappie, T. A.; Humphrey, J. M.; Allen, M. P.; Estep, K. G.; Fox, C. B.; Lebel, L. A.; Liras, S.; Marr, E. S.; Menniti, F. S.; Pandit, J.; Schmidt, C. J.; Tu, M.; Williams, R. D.; Yang, F. V. Discovery of a series of 6, 7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors. J. Med. Chem., 2007, 50, 182-185. (Pubitemid 46147698)
69. Reneerkens, O. A.; Rutten, K.; Bollen, E.; Hage, T.; Blokland, A.; Steinbusch, H. W.; Prickaerts, J. Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behav. Brain Res., 2013, 236, 16-22.
70. Zhang, Z.; Lu, X.; Xu, J.; Rothfuss, J.; Mach, R. H.; Tu, Z. Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A. Eur. J. Med. Chem., 2011, 46, 3986-3995.
71. Hu, E.; Kunz, R. K.; Rumfelt, S.; Andrews, K. L.; Li, C.; Hitchcock, S. A.; Lindstrom, M.; Treanor, J. Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3). Bioorg. Med. Chem. Lett., 2012, 22, 6938-6942.
72. Tu, Z.; Xu, J.; Jones, L. A.; Li, S.; Mach, R. H. Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation. Nucl. Med. Biol., 2010, 37, 509-516.
73. Verhoest, P. R.; Helal, C. J.; Hoover, D. J.; Humphrey, J. M. Heteroaromatic quinoline compounds as phosphodiesterase inhibitors, their preparation, pharmaceutical compositions, and use in therapy. WO2006072828, 2006.
74. De Martinis, N.; Banerjee, A.; Kumar, V.; Boyer, S.; Schmidt, C.; Arroyo, S. Results of a phase 2A proof-of-concept trial with a PDE10A inhibitor in the treatment of acute exacerbation of schizophrenia. Schizophr. Res., 2012, 136, S262.
75. Verhoest, P. R.; Helal, C. J. Bicyclic heteroaryl compounds as PDE10A inhibitors. US20070155779, 2007.
76. Verhoest, P. R. Tricyclic heteroaryl compounds as PDE10A inhibitors. WO2008001182, 2008.
77. Asproni, B.; Murineddu, G.; Pau, A.; Pinna, G. A.; Langgard, M.; Christoffersen, C. T.; Nielsen, J.; Kehler, J. Synthesis and SAR study of new phenylimidazole-pyrazolo[1, 5-c]quinazolines as potent phosphodiesterase 10A inhibitors. Bioorg. Med. Chem., 2011, 19, 642-649.
78. Yang, S. W.; Smotryski, J.; McElroy, W. T.; Tan, Z.; Ho, G.; Tulshian, D.; Greenlee, W. J.; Guzzi, M.; Zhang, X.; Mullins, D.; Xiao, L.; Hruza, A.; Chan, T. M.; Rindgen, D.; Bleickardt, C.; Hodgson, R. Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia. Bioorg. Med. Chem. Lett., 2012, 22, 235-239.
79. McElroy, W. T.; Tan, Z.; Basu, K.; Yang, S. W.; Smotryski, J.; Ho, G. D.; Tulshian, D.; Greenlee, W. J.; Mullins, D.; Guzzi, M.; Zhang, X.; Bleickardt, C.; Hodgson, R. Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound. Bioorg. Med. Chem. Lett., 2012, 22, 1335-1339.
80. Ho, G. D.; Yang, S. W.; Smotryski, J.; Bercovici, A.; Nechuta, T.; Smith, E. M.; McElroy, W.; Tan, Z.; Tulshian, D.; McKittrick, B.; Greenlee, W. J.; Hruza, A.; Xiao, L.; Rindgen, D.; Mullins, D.; Guzzi, M.; Zhang, X.; Bleickardt, C.; Hodgson, R. The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia. Bioorg. Med. Chem. Lett., 2012, 22, 1019-1022.
81. Wu, Q.; Gao, Q.; Guo, H.; Li, D.; Wang, J.; Gao, W.; Han, C.; Li, Y.; Yang, L. Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis. Mol. Biosyst., 2013, 9, 386-397.
82. Ventura, C.; Martins, F. Application of quantitative structureactivity relationships to the modeling of antitubercular compounds. 1. The hydrazide family. J. Med. Chem., 2008, 51, 612-624. (Pubitemid 351252289)
83. Hernandez, P.; Rojas, R.; Gilman, R. H.; Sauvain, M.; Lima, L. M.; Barreiro, E. J.; Gonzalez, M.; Cerecetto, H. Hybrid furoxanyl Nacylhydrazone derivatives as hits for the development of neglected diseases drug candidates. Eur. J. Med. Chem., 2013, 59, 64-74.
84. Gage, J. L.; Onrust, R.; Johnston, D.; Osnowski, A.; Macdonald, W.; Mitchell, L.; Urogdi, L.; Rohde, A.; Harbol, K.; Gragerov, S.; Dorman, G.; Wheeler, T.; Florio, V.; Cutshall, N. S. NAcylhydrazones as inhibitors of PDE10A. Bioorg. Med. Chem. Lett., 2011, 21, 4155-4159.
85. Cutshall, N. S.; Onrust, R.; Rohde, A.; Gragerov, S.; Hamilton, L.; Harbol, K.; Shen, H. R.; McKee, S.; Zuta, C.; Gragerova, G.; Florio, V.; Wheeler, T. N.; Gage, J. L. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia. Bioorg. Med. Chem. Lett., 2012, 22, 5595-5599.
86. NewsHD. Available from: http://www.newshd.net/articles/3775/ investigational-new-drug-application-cleared-by-fda-foroms824-in-huntingtons- disease/(Accessed June 13, 2013).
87. Law, R.; Barker, O.; Barker, J. J.; Hesterkamp, T.; Godemann, R.; Andersen, O.; Fryatt, T.; Courtney, S.; Hallett, D.; Whittaker, M. The multiple roles of computational chemistry in fragment-based drug design. J. Comput. Aided Mol. Des., 2009, 23, 459-473.
88. Feng, B.; Mills, J. B.; Davidson, R. E.; Mireles, R. J.; Janiszewski, J. S.; Troutman, M. D.; de Morais, S. M. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dispos., 2008, 36, 268-275. (Pubitemid 351185738)
89. Raheem, I. T.; Breslin, M. J.; Fandozzi, C.; Fuerst, J.; Hill, N.; Huszar, S.; Kandebo, M.; Kim, S. H.; Ma, B.; McGaughey, G.; Renger, J. J.; Schreier, J. D.; Sharma, S.; Smith, S.; Uslaner, J.; Yan, Y.; Coleman, P. J.; Cox, C. D. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg. Med. Chem. Lett., 2012, 22, 5903-5908.
90. Smith, S. M.; Uslaner, J. M.; Cox, C. D.; Huszar, S. L.; Cannon, C. E.; Vardigan, J. D.; Eddins, D.; Toolan, D. M.; Kandebo, M.; Yao, L.; Raheem, I. T.; Schreier, J. D.; Breslin, M. J.; Coleman, P. J.; Renger, J. J. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology, 2013, 64, 215-223.
91. Kehler, J.; Kilburn, J. P. Patented PDE10A inhibitors: novel compounds since 2007. Expert Opin. Ther. Pat., 2009, 19, 1715-1725.
92. Chappie, T. A.; Helal, C. J.; Hou, X. Current landscape of phosphodiesterase 10A (PDE10A) inhibition. J. Med. Chem., 2012, 55, 7299-7331.
93. Kehler, J. Phosphodiesterase 10A inhibitors: a 2009-2012 patent update. Expert Opin. Ther. Pat., 2013, 23, 31-45.
94. Dedeurwaerdere, S.; Wintmolders, C.; Vanhoof, G.; Langlois, X. Patterns of brain glucose metabolism induced by phosphodiesterase 10A inhibitors in the mouse: a potential translational biomarker. J. Pharmacol. Exp. Ther., 2011, 339, 210-217.
95. Andres, J. I.; De Angelis, M.; Alcazar, J.; Celen, S.; Bormans, G. Recent advances in positron emission tomography (PET) radiotracers for imaging phosphodiesterases. Curr. Top. Med. Chem., 2012, 12, 1224-1236.